ENGINEERING MEDICINES TO IMPROVE PATIENT CARE

Investors

Corporate Profile

Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company recently initiated its first global Phase 3 trial called ‘THRIVE’ to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing two candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.

Viridian is based in Waltham, Massachusetts, with offices in Boulder, CO and New York, NY
 

Stock Information

Viridian Therapeutics (NASDAQ - VRDN)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Contact

Louisa Stone
Manager, Investor Relations
IR@viridiantherapeutics.com
508.808.2400

Todd James
Senior Vice President
Corporate Affairs and Investor Relations

Corporate Presentation

February 1, 2023
Viridian Therapeutics Corporate Overview – February 2023
Download PDF